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Research
Symptoms of anxiety and depression in childhood and use of
MDMA: prospective, population based study
Anja C Huizink, Robert F Ferdinand, Jan van der Ende, Frank C Verhulst
Abstract
Objective To investigate whether using ecstasy
(3,4-methylenedioxymethamphetamine, MDMA) is preceded by
symptoms of behavioural and emotional problems in
childhood and early adolescence.
Design Prospective, longitudinal, population based study
Setting The Dutch province of Zuid-Holland.
Participants A sample of 1580 individuals, followed up across a
14 year period, from childhood into adulthood.
Main outcome measures The first assessment took place in
1983 before MDMA appeared as a recreational drug in the
Netherlands and included the child behaviour checklist to
obtain standardised parents’ reports of their children’s
behavioural and emotional problems. Use of the drug was
assessed with the composite international diagnostic interview
14 years later.
Results Eight syndrome scales of childhood behaviour were
examined. Scores in the deviant range for the scales designated
as anxious or depressed in childhood were significantly related
to use of MDMA in adolescents and adults, resulting in an
increased risk (hazard ratio 2.22, 95% confidence interval 1.20
to 4.11, P = 0.01).
Conclusions Individuals with childhood symptoms of anxiety
and depression may have an increased tendency to use MDMA
in adolescence or young adulthood. Its effects are supposed to
include enhanced feelings of bonding with other people,
euphoria, or relaxation. Especially individuals with symptoms of
anxiety or depression may be susceptible to these positive
effects.
Introduction
Ecstasy (3,4-methylenedioxymethamphetamine, MDMA)
emerged as a new drug in Europe more than a decade ago. In the
Netherlands, the drug became available at dance parties from
1985 onwards. Its most frequent users are adolescents who go
out to dance parties.1 In the Netherlands, the age of users is
20-24. In this age group, the number of users has grown in the
past few years, with a lifetime prevalence of 13.2% in 2001 com-
pared with 6.2% in 1997. The prevalence of MDMA use in the
preceding month also increased, from 1.9% in 1997 to 2.9% in
2001.2 Recently, the adverse effects of using MDMA have raised
considerable interest, including its neurotoxic effects.3 Several
studies have indicated that using MDMA is associated with emo-
tional health problems, such as depression, psychotic symptoms,
and anxiety disorders.4–7 These associations may represent two
basic temporal pathways: either emotional problems are a
consequence of using MDMA, or emotional problems lead to
ecstasy use—for example, in order to “self medicate” symptoms.
These two pathways do not exclude each other. Links between
emotional problems and MDMA use may run in both directions,
from emotional problems towards use of the drug and vice versa.
Since most studies were cross sectional and based on clinical
samples, we lack insight in these temporal pathways. Most
authors argue for the first option and refer to neurotoxic effects
of MDMA on serotonergic neurones.8–12 However, a study by
Lieb et al has shown that the first use of MDMA was secondary
to phobias, somatoform disorders, dysthymia, and panic disorder
or agoraphobia.5 The study did not focus on other psychiatric
disorders, such as delinquent, aggressive behaviour, or attention
problems in relation to ecstasy use.
We investigated whether use of MDMA is preceded by symp-
toms of behavioural and emotional problems in childhood and
early adolescence. For this purpose, we assessed MDMA use in a
sample of 1580 individuals, who were followed up for a period of
14 years, from childhood into adulthood. The first assessment
took place in 1983 before MDMA appeared as a recreational
drug in the Netherlands. The subjects in our study had therefore
probably not used MDMA at the first assessment. This offered us
the unique opportunity to investigate if a pathway from
behavioural and emotional problems leading to MDMA use
exists.
Methods
Participants
This study was part of an ongoing longitudinal general popula-
tion study that started in 1983 in the Dutch province of
Zuid-Holland. The investigators drew a random sample of 2600
children and adolescents aged 4-17 from municipal registers
that list all residents. Of the 2447 parents who were contacted,
2076 (84.8%) cooperated. After the first measurement (1983),
the sample was approached again in 1985, 1987, 1989, 1991, and
1997. More details on the initial data collection are presented
elsewhere.13 14
In 1997 (at follow-up) we reassessed 1580 individuals with
the computerised version of the composite international
diagnostic interview15 to determine psychiatric diagnoses
according to the Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition (DSM-IV).16 The response rate was 79% after
correction for deceased subjects (n = 8), mentally retarded
subjects (n = 12), and emigrated subjects (n = 59). Scores for
1983 from the child behaviour checklist scores were similar for
dropouts and for children who remained in the study.17
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Procedures
In 1983 the researchers used the child behaviour checklist
(CBCL) to obtain standardised parent reports of their children’s
behavioural and emotional problems. The checklist includes 120
problem items, which are scored 0 (not true), 1 (somewhat or
sometimes true), and 2 (very true or often true), based on the
preceding six months.18 Eight syndrome scores are derived: with-
drawn, somatic complaints, anxious or depressed, social
problems, thought problems, attention problems, delinquent
behaviour, and aggressive behaviour. Good reliability and valid-
ity of the checklist have been replicated for the Dutch
translation.19 Kasius et al reported strong associations between
syndrome scores on the child behaviour checklist and DSM-IV
diagnoses that were derived from standardised diagnostic inter-
view, in a Dutch psychiatric outpatient sample of 231 youngsters
aged 6-16.20
We dichotomised syndrome scores on the CBCL as deviant
and non-deviant. To select individuals who could be regarded as
deviant, we used the cut-off points reflecting the 95th percentile
of the cumulative frequency distribution of these scales in a
Dutch normative sample, for each age group (4-11, 12-17) and
sex separately, as recommended by Achenbach.18 These cut-off
points are widely used in clinical practice and were established by
comparing large samples of clinically referred children with
non-referred children, to divide children on the basis of their
scores into those who resemble normal children and those who
resemble children with disorders.18
At follow-up in 1997, we used the lifetime version of the
composite international diagnostic interview (CIDI), version
2.1,15 to assess use of MDMA. This instrument allows for the
standardised assessment of psychiatric symptoms, syndromes,
and diagnoses of a wide range of DSM-IV substance use and
mental disorders, along with information about onset, duration,
and clinical and psychosocial severity. Good reliability and valid-
ity have been reported for the CIDI.21 For this study, we defined
lifetime use of MDMA as having used the drug on at least five
occasions, to indicate those users only who progressed from
experimentation with the drug to more regular use. The item of
the CIDI regarding MDMA use represents one of the DSM-IV
criteria of drug abuse. We also assessed age at first use (onset).
The investigators used a six point scale of parental
occupation22 with 1 = lowest and 6 = highest to measure
socioeconomic status of the parents in 1983. If both parents
worked we used the highest occupational level. For this study we
used a dichotomised score, indicating a low socioeconomic status
(scores 1-3) and a medium to high status (scores 4-6).
At each phase, all subjects who completed a questionnaire
(parents and youths) gave written informed consent after the
procedure had been fully explained.
Statistical analyses
We used SAS, version 9.1 (SAS Institute, Cary, NC, 2002-2003) to
conduct Cox regression analyses.23 In the analysis, we
determined whether behavioural and emotional problems in
childhood or early adolescence, measured in 1983, were a risk
factor for later use of MDMA. During interviews, the age of onset
could be determined only as a whole number of years, and
therefore, we defined survival time in years as age at onset of use
of MDMA, or, if this did not occur, as the age at the final assess-
ment, in 1997. Since we knew the survival time only in years, we
used the exact method in SAS for the treatment of ties. We
assessed subjects first at ages 4-17, therefore we accounted for
left truncation of survival times. We computed hazard ratios that
indicate a considerable association between behavioural and
emotional in 1983. We adjusted for possible cohort effects by fit-
ting stratified Cox regressions, in which we used age groups in
1983 as strata. We further adjusted for the possible effects of
socioeconomic status and tested for interaction effects of sex
with the predictors. The proportional hazards assumption was
not violated in any of the conducted analyses. We assumed statis-
tical significance at the level of P < 0.05.
Results
Descriptive analyses
The mean age of participants was 9.9 in 1983 (range 4-17) and
24.5 in 1997 (range 18-33). Both sexes were represented in the
sample, with slightly more female than male participants
(n = 1060 (51.1%) v n = 1016 (48.9%)). In 1997, data were
available for 76% (n = 1580) of the original sample in 1983. In
1997, 98 study participants (4.7% of the total sample)—64 male
and 34 female—reported using MDMA on at least five occasions.
We dichotomised scores on all CBCL scales. Table 1 shows
separately the numbers of male and female participants in the
deviant range groups in 1983. In addition, it shows the numbers
of male and female participants in the deviant range groups in
1983 who reported having used MDMA at least five times in
1997.
Ninety MDMA users (92%) had also experimented with
other drugs, most commonly with cannabis, 58 with cocaine
(59%), and 43 with psychedelic drugs (44%). Of interest is that 59
MDMA users had tried cannabis only once (60%), whereas of
those who used both cocaine and ecstasy, 63 tried cocaine two to
four times (64%) and those who used psychedelic drugs and
MDMA, used these on two to four occasions (49%, n = 48) or
even on at least five occasions (49%, n = 48).
Survival analyses
Firstly, we carried out separate Cox regression analyses with each
dichotomised CBCL scale score as predictor and time of onset of
ecstasy use as outcome, adjusting for socioeconomic status and
sex, and including sex by syndrome scale interaction terms (none
of which reached significance). This may be because only few
events are included in our study. Therefore we deleted the inter-
action terms from the Cox regression analyses reported in table
2. On the basis of the associations shown in table 2, we included
predictors with P values < 0.10 in the next model. We therefore
included scores within the deviant range of the anxious or
Table 1 Number (percentages) of subjects in deviant range groups and
number of subjects within deviant range groups that reported to have used
ecstasy in 1997
CBCL scale in 1983
Boys in
deviant
range*
Boys in deviant
range, using
MDMA in
1997†
Girls in
deviant
range*
Girls in deviant
range, using
MDMA in 1997†
Withdrawn 60 (8) 4 (7) 68 (8) 2 (3)
Somatic complaints 39 (5) 3 (8) 34 (4) 0 (0)
Anxious/depressed 61 (8) 9 (15) 58 (7) 3 (5)
Social problems 66 (9) 2 (3) 79 (9) 2 (3)
Thought problems 26 (4) 3 (12) 16 (2) 0 (0)
Attention problems 95 (13) 6 (1) 75 (9) 1 (1)
Delinquent behaviour 92 (13) 13 (14) 56 (7) 0 (0)
Aggressive behaviour 99 (14) 8 (8) 87 (10) 0 (0)
In 1983, 1016 boys and 1060 girls were included in the study, and in 1997, 732 male
subjects and 848 female subjects. At follow-up in 1997, 64 (9%) of male subjects and 34
(4%) of female subjects used MDMA.
*The percentages reflect the number of individuals with scores in the deviant range of the
respective syndrome scales divided by the number of (male or female) individuals in 1997.
†The percentages reflect the number of individuals who used MDMA in 1997 divided by the
number of individuals with scores in the deviant range of the respective syndrome scales.
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depressed syndrome scale and delinquent behaviour syndrome
scale in 1983 as predictors in the multivariate model, which was
stratified for age, and adjusted for socioeconomic status and sex
by syndrome scale interaction effects. The final model included
only one significant predictor—scores within the deviant range of
the anxious or depressed syndrome scale at baseline (1983) on
MDMA use, stratified for age, and adjusted socioeconomic status
and sex by syndrome scale interaction effects, resulting in an
increased risk on later MDMA use (hazard ratio 2.22, 95% confi-
dence interval 1.20 to 4.11, P = 0.01).
Discussion
We found evidence for an increased risk for use of MDMA in
individuals who scored in the deviant range of the anxious or
depressed scale of the child behaviour checklist in 1983. We
found no associations between the other CBCL syndrome scales
and use of MDMA. We studied whether behavioural and
emotional problems in childhood and early adolescence
preceded the use of MDMA, because the first measurement of
related symptoms in childhood and early adolescence took place
before MDMA appeared in the Netherlands.
Comparison with other studies
These findings partly confirm previous findings of Lieb et al,
who showed that subjects with emotional disorders such as pho-
bia, and somatoform conditions at baseline (age 14-24) showed a
significantly increased risk of starting to use MDMA during a
four year follow-up period.5 We did not find a relation for
somatoform conditions in childhood and use of MDMA in ado-
lescence. Our study used a 14 year follow-up, whereas Lieb et al
had a much shorter time span between determinants and
outcome measures.5 Also, in their study the assessment of the use
of MDMA before their baseline measurement was retrospective
and may have been subject to recall bias. In contrast, our first
assessment of risk factors took place before MDMA appeared in
the Netherlands, and therefore, the subjects could have started
using it only after our first assessment.
We found an effect of symptoms of anxiety and depression
on later MDMA use for male as well as female study participants.
This finding contradicts other, mostly cross sectional, studies
showing the strongest association between depressive and anxi-
ety symptoms and substance use in young women.24 25 However,
these associations have been examined in clinical samples,
including individuals with more serious psychiatric and
substance use disorders than our population based sample.
Examining sex specific vulnerabilities for MDMA use will be a
challenge in future studies.
Meaning of the study
Although we performed multiple tests and should therefore
interpret our findings cautiously, the results imply that individu-
als with childhood symptoms of anxiety and depression may
have an increased tendency to use MDMA. The drug’s effects are
supposed to include enhanced feelings of bonding with other
people, euphoria, or relaxation. Especially individuals with
symptoms of anxiety or depression may be susceptible to these
positive effects of MDMA. Studies on motivations of MDMA
users showed that alleviation of depressed mood, desire for an
altered state of mind, desire to escape, and self medication are
among often mentioned reasons to use MDMA.26 27 The active
compound affects the serotonin system, which is known to be
important in the regulation of mood. MDMA produces an acute,
rapid enhancement in the release of serotonin from nerve end-
ings in the brains of experimental animals.28 This acute effect
relates to the enhanced positive feelings. Individuals with signs of
anxiety and depression may therefore use MDMA to self
medicate their symptoms.
Possible reasons for using MDMA
Other studies have supported the relation between MDMA use
as determinant and depression as outcome.29–31 It has been
found, for example, that in the long run, exposure to MDMA
may result in increased depressive symptoms. In animals, chronic
exposure to MDMA resulted in neurotoxic effects such as inhibi-
tion of serotonin reuptake into the neurone and serotonin
synthesis, and destruction of serotonergic axon terminals.32 This
neurodegeneration is associated with a decline in concentrations
of serotonin in the brain, and decreased availability of serotonin
in the central nervous system has been proposed as the basis for
the symptoms of depression.33 34 However, our findings show that
individuals who already had depressive symptoms in childhood
or adolescence have an increased risk of starting to use MDMA.
In turn, this may affect the serotonin system, which may increase
the risk of these individuals developing a mood disorder at a
later age after using MDMA. This may explain part of the
association that has been found between MDMA use and later
depression in other studies. Of course, other mechanisms may be
involved in the relation between mood disorders and MDMA
use. For example, a common underlying genetic vulnerability
may account for symptoms of mood disorders and the propen-
sity to use drugs such as ecstasy. Lieb et al showed that
depression in parents is associated with depression and
substance use disorders in offspring.35
Other factors may account for the increased tendency to use
MDMA in some individuals. Their social environment will prob-
ably play a part and can include peers that take risks or use or
have access to illicit drugs,36 and therefore, the availability of
ecstasy will be increased. Other potential risk factors, which we
have not tested in this study, may include the desire to party, nov-
elty seeking, other drug use of adolescents, social roles in peer
groups, substance use of parents, and bad parenting practices.
Furthermore, the pathway from emotional problems in
childhood towards later use of MDMA may be non-specific. In
our sample, many users of MDMA have also used other
stimulant drugs on several occasions, such as cocaine and psych-
edelic drugs.
Conclusion
Our findings give evidence for a temporal pathway, in which
childhood symptoms of anxiety and depression may precede use
of MDMA. Focusing on the children with symptoms of anxiety
and depression as vulnerable individuals in future studies will
increase our insight into the potential harmful effects of MDMA
Table 2 Separate Cox regression analyses for each syndrome on the
childhood behaviour checklist (CBCL)
CBCL scale in 1983 Hazard ratio (95% CI) P value
Withdrawn 0.97 (0.43 to 2.24) 0.95
Somatic complaints 0.73 (0.23 to 2.30) 0.58
Anxious or depressed 2.22 (1.20 to 4.11) 0.01
Social problems 0.73 (0.27 to 2.00) 0.54
Thought problems 1.64 (0.51 to 5.22) 0.40
Attention problems 0.86 (0.39 to 1.87) 0.70
Delinquent behaviour 1.81 (1.00 to 3.28) 0.05
Aggressive behaviour 0.94 (0.45 to 1.95) 0.87
Associations were stratified for age and adjusted for socioeconomic status and sex.
Associations are shown between each CBCL syndrome scale measured in 1983 and MDMA
use measured in 1997.
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on brain neurotransmitter systems and associated psychopathol-
ogy. Moreover, the reward mechanisms involved in the plausible
“self medication” attempts of vulnerable individuals need to be
examined, to prevent adolescents and young adults from using
MDMA regularly.
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What is already known on this topic
The use of ecstasy (3,4-methylenedioxymethamphetamine,
MDMA) is associated with emotional health problems, such
as depression, psychotic symptoms, and anxiety disorders
Insight into temporal pathways that explain links between
emotional problems and ecstasy use is lacking
What this study adds
Individuals with childhood symptoms of anxiety and
depression may have an increased tendency to use ecstasy
in adolescence or young adulthood
Focusing on these vulnerable individuals in future studies
will increase our insight into the potential harmful effects of
MDMA on brain neurotransmitter systems and associated
psychopathology
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